secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001789769-24-000100
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q3 net loss $3.54/sh; cash $122.9M; licensed PD-L1xVEGF bispecific SYN-2510
--------------------------------------------------------------------------------

- Licensed SYN-2510 (PD-L1xVEGF bispecific) and SYN-27M (CTLA-4 antibody) from ImmuneOnco for global ex-China rights.
- Clinical data update for SYN-2510 monotherapy in China expected 1H 2025; Phase 1b/2 combo in NSCLC late 2024, TNBC 1H 2025 in China.
- U.S. study of SYN-2510 in NSCLC targeted to start 2H 2025.
- Cash, equivalents & securities $122.9M as of Sept 30, 2024 (down from $175.0M Dec 31, 2023); cash runway beyond 2026.
- Q3 2024 net loss $3.54 per share vs $10.37 in Q3 2023; non-GAAP loss $2.55 vs $2.53.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/0001789769-24-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976924000100/til-20241113.htm
  HTML page:      https://secwatch.observer/filing/0001789769-24-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer